Tocilizumab, a Humanized Monoclonal Antibody Against the Interleukin-6 Receptor, Inhibits High Glucose-Induced Vascular Smooth Muscle Cell Migration Through Mitogen-Activated Protein Kinase Signaling Pathways

doi:10.1089/jir.2018.0009

CNU IR > College of Smart Living > Dept. of Senior Service and Health Management > Periodical Articles > Item 310902800/32232

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32232

Title:	Tocilizumab, a Humanized Monoclonal Antibody Against the Interleukin-6 Receptor, Inhibits High Glucose-Induced Vascular Smooth Muscle Cell Migration Through Mitogen-Activated Protein Kinase Signaling Pathways
Authors:	Wu, Tao-Cheng Chiang, Chih-Yao Chan, Jenq-Shyong Lee, Chiu-Yang Leu, Hsin-Bang Huang, Po-Hsun Chen, Jia-Shiong Lin, Shing-Jong Chen, Jaw-Wen
Contributors:	Natl Yang Ming Univ, Cardiovasc Res Ctr Taipei Vet Gen Hosp, Div Cardiol, Dept Med Taipei City Hosp, Div Cardiovasc Surg Armed Forces Tao Yuan Gen Hosp, Div Nephrol Taipei Vet Gen Hosp, Div Cardiovasc Surg, Dept Surg Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management Taipei Vet Gen Hosp, Hlth Care & Serv Ctr Taipei Vet Gen Hosp, Dept Med Res & Educ Natl Yang Ming Univ, Inst Pharmacol, Inst Clin Med, Sch Med
Keywords:	tocilizumab human aortic smooth muscle cells interleukin-6 receptor glucose diabetes
Date:	2018-11-01
Issue Date:	2019-11-15 15:46:05 (UTC+8)
Publisher:	MARY ANN LIEBERT, INC
Abstract:	Rheumatoid arthritis (RA) with diabetes increases the risk of cardiovascular diseases. Interleukin-6 (IL-6) promotes the disease activity of RA and insulin resistance. This study aimed to evaluate the potential effects and molecular mechanisms of IL-6 blocker, tocilizumab, in atherosclerosis with diabetes. Human aortic smooth muscle cells (HASMCs) cultured under hyperglycemic conditions were evaluated for migration, expression of adhesion molecules, and matrix metalloproteinases before and after treatment with tocilizumab. High glucose (HG) significantly increased expression of IL-6, intercellular adhesion molecule (ICAM-1), matrix metalloproteinase-2 & 9, and migration of vascular smooth muscle cells. Tocilizumab suppressed HG-induced expression of ICAM-1, MMP-2, and MMP-9. Pretreatment with tocilizumab also inhibited migration, MAPK signaling, and nuclear translocation of p65-NF-kappa B in HG-stimulated HASMCs. Our data suggested that tocilizumab may exert an antiatherosclerotic activity in diabetes.
???metadata.dc.relation.uri???:	http://dx.doi.org/10.1089/jir.2018.0009
Relation:	Cancers, v.38, n.11, pp.510-516
Appears in Collections:	[Dept. of Senior Service and Health Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1390	View/Open

Loading...